Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

WILLIAM JUSTIZ

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1275583916
CMS profile
542734
Location
NAPLES, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$3,604.93

55 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,849.35 49
Travel and Lodging $1,755.58 6

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 2; records 51–55 of 55 matching records. This page contains 5 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

WILLIAM JUSTIZ

NPI 1275583916 · CMS profile ID 542734

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

NAPLES, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–55 of 55 matching records. This page contains 5 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1275583916?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
WILLIAM JUSTIZ, NPI 1275583916, CMS profile ID 542734. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–55 of 55 matching records. This page contains 5 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1275583916?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). WILLIAM JUSTIZ, NPI 1275583916, CMS profile ID 542734. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–55 of 55 matching records. This page contains 5 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1275583916?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
WILLIAM JUSTIZ, NPI 1275583916, CMS profile ID 542734, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–55 of 55 matching records. This page contains 5 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1275583916?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

55 matching records · $3,604.93 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 55 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–55 of 55.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Alnylam Pharmaceuticals Inc. $261.0101/30/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006133717 CMS
Novartis Pharmaceuticals Corporation $16.6601/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992282165 CMS
Alnylam Pharmaceuticals Inc. $518.5601/20/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006133701 CMS
Avion Pharmaceuticals $22.5901/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032987483 CMS
Horizon Therapeutics plc $22.6601/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 987026521 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $680.44 50
PY2020 $359.97 21
PY2021 $547.68 30
PY2022 $1,957.97 43
PY2023 $3,604.93 55
PY2024 $2,805.17 60
PY2025 $2,641.44 68

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,433,037.45 114
PY2024 Recipient $11,500.00 1
PY2024 Principal investigator $1,119,128.46 85
PY2023 Recipient $868.68 2
PY2023 Principal investigator $1,140,546.20 108
PY2022 Recipient $300.00 1
PY2022 Principal investigator $1,012,806.40 53
PY2021 Recipient $24,439.97 2
PY2021 Principal investigator $512,290.41 52
PY2020 Principal investigator $472,904.68 103
PY2019 Principal investigator $357,468.38 76

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

114 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Alnylam Pharmaceuticals Inc. $48.00 12/31/2025 Non-covered Recipient Entity
Aqualane Clinical Research
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215511091
Principal investigator 1 Janssen Research & Development, LLC $54,762.00 12/22/2025 Non-covered Recipient Entity
AQUALANE CLINICAL RESEARCH LLC
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175428018
Principal investigator 1 Novo Nordisk AS $950.62 12/22/2025 Non-covered Recipient Entity
COLLIER NEUROLOGIC SPECIALISTS, LLC
NN6535-4725 No dispute reported 06/30/2026 1213770134
Principal investigator 1 Janssen Research & Development, LLC $12,085.00 12/15/2025 Non-covered Recipient Entity
AQUALANE CLINICAL RESEARCH LLC
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175428074
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,629.00 12/03/2025 Non-covered Recipient Entity
Aqualane Clinical Research LLC
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215509794
Principal investigator 1 Alnylam Pharmaceuticals Inc. $381.00 12/03/2025 Non-covered Recipient Entity
Aqualane Clinical Research LLC
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215509798
Principal investigator 1 Alnylam Pharmaceuticals Inc. $381.00 12/03/2025 Non-covered Recipient Entity
Aqualane Clinical Research LLC
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215509803
Principal investigator 1 Alnylam Pharmaceuticals Inc. $16,067.00 12/03/2025 Non-covered Recipient Entity
Aqualane Clinical Research LLC
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215509807
Principal investigator 1 Alnylam Pharmaceuticals Inc. $381.00 12/03/2025 Non-covered Recipient Entity
Aqualane Clinical Research LLC
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215509811
Principal investigator 1 Alnylam Pharmaceuticals Inc. $381.00 12/03/2025 Non-covered Recipient Entity
Aqualane Clinical Research LLC
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215509815
Principal investigator 1 Alnylam Pharmaceuticals Inc. $381.00 12/03/2025 Non-covered Recipient Entity
Aqualane Clinical Research LLC
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215509818
Principal investigator 1 Alnylam Pharmaceuticals Inc. $11,846.00 12/03/2025 Non-covered Recipient Entity
Aqualane Clinical Research LLC
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215509825
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,666.00 12/03/2025 Non-covered Recipient Entity
Aqualane Clinical Research LLC
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215509829
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,595.00 12/01/2025 Non-covered Recipient Entity
Aqualane Clinical Research LLC
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215509742
Principal investigator 1 Alnylam Pharmaceuticals Inc. $138.00 12/01/2025 Non-covered Recipient Entity
Aqualane Clinical Research LLC
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215509790
Principal investigator 1 Alnylam Pharmaceuticals Inc. $11,846.00 11/19/2025 Non-covered Recipient Entity
Aqualane Clinical Research LLC
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215509769
Principal investigator 1 Alnylam Pharmaceuticals Inc. $381.00 11/19/2025 Non-covered Recipient Entity
Aqualane Clinical Research LLC
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215509772
Principal investigator 1 Alnylam Pharmaceuticals Inc. $14,954.00 11/19/2025 Non-covered Recipient Entity
Aqualane Clinical Research LLC
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215509775
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,261.00 11/19/2025 Non-covered Recipient Entity
Aqualane Clinical Research LLC
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215509779
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,865.00 11/19/2025 Non-covered Recipient Entity
Aqualane Clinical Research LLC
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215509782
Principal investigator 1 Alnylam Pharmaceuticals Inc. $381.00 11/19/2025 Non-covered Recipient Entity
Aqualane Clinical Research LLC
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215509786
Principal investigator 1 Alnylam Pharmaceuticals Inc. $48.00 10/31/2025 Non-covered Recipient Entity
Aqualane Clinical Research
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215511083
Principal investigator 1 Janssen Research & Development, LLC $23,013.00 10/31/2025 Non-covered Recipient Entity
AQUALANE CLINICAL RESEARCH LLC
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175427950
Principal investigator 1 Janssen Research & Development, LLC $2,514.00 10/31/2025 Non-covered Recipient Entity
AQUALANE CLINICAL RESEARCH LLC
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175428030
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,024.73 10/30/2025 Non-covered Recipient Entity
AQUALANE CLINICAL RESEARCH
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184256423
Principal investigator 1 Alnylam Pharmaceuticals Inc. $48.00 10/28/2025 Non-covered Recipient Entity
Aqualane Clinical Research
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215511087
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $16,200.00 10/24/2025 Non-covered Recipient Entity
Aqualane Clinical Research
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimers Disease (ADEPT-4) No dispute reported 06/30/2026 1235998963
Principal investigator 1 Alnylam Pharmaceuticals Inc. $16,067.00 10/16/2025 Non-covered Recipient Entity
Aqualane Clinical Research LLC
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215509746
Principal investigator 1 Alnylam Pharmaceuticals Inc. $381.00 10/16/2025 Non-covered Recipient Entity
Aqualane Clinical Research LLC
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215509751
Principal investigator 1 Alnylam Pharmaceuticals Inc. $381.00 10/16/2025 Non-covered Recipient Entity
Aqualane Clinical Research LLC
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215509754
Principal investigator 1 Alnylam Pharmaceuticals Inc. $381.00 10/16/2025 Non-covered Recipient Entity
Aqualane Clinical Research LLC
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215509758
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,865.00 10/16/2025 Non-covered Recipient Entity
Aqualane Clinical Research LLC
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215509762
Principal investigator 1 Alnylam Pharmaceuticals Inc. $381.00 10/16/2025 Non-covered Recipient Entity
Aqualane Clinical Research LLC
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215509766
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $258.00 10/15/2025 Non-covered Recipient Entity
AQUALANE CLINICAL RESEARCH
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184250455
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,120.00 10/15/2025 Non-covered Recipient Entity
AQUALANE CLINICAL RESEARCH
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184250457
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,699.00 10/03/2025 Non-covered Recipient Entity
Aqualane Clinical Research LLC
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215509832
Principal investigator 1 Alnylam Pharmaceuticals Inc. $48.00 09/30/2025 Non-covered Recipient Entity
Aqualane Clinical Research
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215511015
Principal investigator 1 Janssen Research & Development, LLC $8,380.00 09/29/2025 Non-covered Recipient Entity
AQUALANE CLINICAL RESEARCH LLC
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175427970
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $173.34 09/24/2025 Non-covered Recipient Entity
Aqualane Clinical Research
Phase III Safety and Efficacy of KarXT in Psychosis Associated with AD (ADEPT 4): 2 of 2 Acute Studies No dispute reported 06/30/2026 1235998971
Principal investigator 1 Novo Nordisk AS $3,480.07 09/19/2025 Non-covered Recipient Entity
COLLIER NEUROLOGIC SPECIALISTS, LLC
NN6535-4725 No dispute reported 06/30/2026 1213748864
Principal investigator 1 Janssen Research & Development, LLC $10,406.00 09/01/2025 Non-covered Recipient Entity
AQUALANE CLINICAL RESEARCH LLC
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175427985
Principal investigator 1 Janssen Research & Development, LLC $2,118.00 09/01/2025 Non-covered Recipient Entity
AQUALANE CLINICAL RESEARCH LLC
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175428062
Principal investigator 1 Alnylam Pharmaceuticals Inc. $48.00 08/29/2025 Non-covered Recipient Entity
Aqualane Clinical Research
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215511011
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,337.56 08/28/2025 Non-covered Recipient Entity
AQUALANE CLINICAL RESEARCH
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184230745
Principal investigator 1 Alnylam Pharmaceuticals Inc. $7,679.00 08/15/2025 Non-covered Recipient Entity
Aqualane Clinical Research
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215511022
Principal investigator 1 Alnylam Pharmaceuticals Inc. $810.00 08/15/2025 Non-covered Recipient Entity
Aqualane Clinical Research
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215511026
Principal investigator 1 Alnylam Pharmaceuticals Inc. $375.00 08/13/2025 Non-covered Recipient Entity
Aqualane Clinical Research
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215511034
Principal investigator 1 Alnylam Pharmaceuticals Inc. $4,681.00 08/13/2025 Non-covered Recipient Entity
Aqualane Clinical Research
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215511039
Principal investigator 1 Alnylam Pharmaceuticals Inc. $210.00 08/13/2025 Non-covered Recipient Entity
Aqualane Clinical Research
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215511044
Principal investigator 1 Alnylam Pharmaceuticals Inc. $936.00 08/13/2025 Non-covered Recipient Entity
Aqualane Clinical Research
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215511050
Principal investigator 1 Alnylam Pharmaceuticals Inc. $57.00 08/13/2025 Non-covered Recipient Entity
Aqualane Clinical Research
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215511054
Principal investigator 1 UCB SA $5,962.00 08/07/2025 Non-covered Recipient Entity
AQUALANE CLINICAL RESEARCH LLC
A MULTICENTER PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF UCB0022 IN STUDY PARTICIPANTS WITH ADVANCED Parkinsons DISEASE No dispute reported 06/30/2026 1246657992
Principal investigator 1 Janssen Research & Development, LLC $24,180.00 08/01/2025 Non-covered Recipient Entity
AQUALANE CLINICAL RESEARCH LLC
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175427956
Principal investigator 1 Janssen Research & Development, LLC $10,756.00 08/01/2025 Non-covered Recipient Entity
AQUALANE CLINICAL RESEARCH LLC
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175427964
Principal investigator 1 Janssen Research & Development, LLC $15,086.00 08/01/2025 Non-covered Recipient Entity
AQUALANE CLINICAL RESEARCH LLC
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175428024
Principal investigator 1 Janssen Research & Development, LLC $7,451.00 08/01/2025 Non-covered Recipient Entity
AQUALANE CLINICAL RESEARCH LLC
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175428045
Principal investigator 1 Alnylam Pharmaceuticals Inc. $48.00 07/31/2025 Non-covered Recipient Entity
Aqualane Clinical Research
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215511008
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $163.25 07/28/2025 Non-covered Recipient Entity
Aqualane Clinical Research
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Psychosis Associated with Alzheimers Disease (ADEPT-5) No dispute reported 06/30/2026 1235998965
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,680.00 07/25/2025 Non-covered Recipient Entity
AQUALANE CLINICAL RESEARCH
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184218629
Principal investigator 1 Alnylam Pharmaceuticals Inc. $11,846.00 07/23/2025 Non-covered Recipient Entity
Aqualane Clinical Research
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215511019
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,200.00 07/07/2025 Non-covered Recipient Entity
Aqualane Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215511030
Principal investigator 1 Janssen Research & Development, LLC $13,455.00 07/03/2025 Non-covered Recipient Entity
AQUALANE CLINICAL RESEARCH LLC
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175427945
Principal investigator 1 Alnylam Pharmaceuticals Inc. $13,945.00 07/02/2025 Non-covered Recipient Entity
Aqualane Clinical Research
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215511058
Principal investigator 1 Alnylam Pharmaceuticals Inc. $13,945.00 07/02/2025 Non-covered Recipient Entity
Aqualane Clinical Research
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215511063
Principal investigator 1 Alnylam Pharmaceuticals Inc. $381.00 07/02/2025 Non-covered Recipient Entity
Aqualane Clinical Research
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215511067
Principal investigator 1 Alnylam Pharmaceuticals Inc. $381.00 07/02/2025 Non-covered Recipient Entity
Aqualane Clinical Research
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215511071
Principal investigator 1 Alnylam Pharmaceuticals Inc. $14,954.00 07/02/2025 Non-covered Recipient Entity
Aqualane Clinical Research
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215511075
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,261.00 07/02/2025 Non-covered Recipient Entity
Aqualane Clinical Research
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215511078
Principal investigator 1 Alnylam Pharmaceuticals Inc. $48.00 06/30/2025 Non-covered Recipient Entity
Aqualane Clinical Research
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215510954
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,865.00 06/23/2025 Non-covered Recipient Entity
Aqualane Clinical Research
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215510962
Principal investigator 1 Alnylam Pharmaceuticals Inc. $11,846.00 06/23/2025 Non-covered Recipient Entity
Aqualane Clinical Research
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215510966
Principal investigator 1 Alnylam Pharmaceuticals Inc. $13,945.00 06/23/2025 Non-covered Recipient Entity
Aqualane Clinical Research
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215510970
Principal investigator 1 Novo Nordisk AS $2,923.32 06/23/2025 Non-covered Recipient Entity
COLLIER NEUROLOGIC SPECIALISTS, LLC
NN6535-4725 No dispute reported 06/30/2026 1213817038
Principal investigator 1 Janssen Research & Development, LLC $9,965.00 06/06/2025 Non-covered Recipient Entity
AQUALANE CLINICAL RESEARCH LLC
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175427991
Principal investigator 1 Alnylam Pharmaceuticals Inc. $48.00 05/30/2025 Non-covered Recipient Entity
Aqualane Clinical Research
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215511114
Principal investigator 1 Alnylam Pharmaceuticals Inc. $620.00 05/16/2025 Non-covered Recipient Entity
Aqualane Clinical Research
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215510958
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,261.00 05/02/2025 Non-covered Recipient Entity
Aqualane Clinical Research
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215510974
Principal investigator 1 Alnylam Pharmaceuticals Inc. $14,954.00 05/02/2025 Non-covered Recipient Entity
Aqualane Clinical Research
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215510978
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,666.00 05/02/2025 Non-covered Recipient Entity
Aqualane Clinical Research
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215510981
Principal investigator 1 Alnylam Pharmaceuticals Inc. $381.00 05/02/2025 Non-covered Recipient Entity
Aqualane Clinical Research
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215510986
Principal investigator 1 Alnylam Pharmaceuticals Inc. $13,945.00 05/02/2025 Non-covered Recipient Entity
Aqualane Clinical Research
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215510991
Principal investigator 1 Janssen Research & Development, LLC $27,583.00 05/02/2025 Non-covered Recipient Entity
AQUALANE CLINICAL RESEARCH LLC
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175428067
Principal investigator 1 Alnylam Pharmaceuticals Inc. $48.00 04/30/2025 Non-covered Recipient Entity
Aqualane Clinical Research
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215511110
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,024.73 04/25/2025 Non-covered Recipient Entity
AQUALANE CLINICAL RESEARCH
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184190157
Principal investigator 1 Novo Nordisk AS $1,877.50 04/21/2025 Non-covered Recipient Entity
COLLIER NEUROLOGIC SPECIALISTS, LLC
NN6535-4725 No dispute reported 06/30/2026 1213804318
Principal investigator 1 Janssen Research & Development, LLC $43,640.00 04/07/2025 Non-covered Recipient Entity
AQUALANE CLINICAL RESEARCH LLC
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175428050
Principal investigator 1 Sage Therapeutics, LLC $11,952.92 04/04/2025 Non-covered Recipient Entity
AQUALANE CLINICAL RESEARCH LLC
Study to Evaluate SAGE-324 in Participants With Essential Tremors No dispute reported 06/30/2026 1206580403
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,666.00 04/02/2025 Non-covered Recipient Entity
Aqualane Clinical Research
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215510995
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,865.00 04/02/2025 Non-covered Recipient Entity
Aqualane Clinical Research
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215510999
Principal investigator 1 Alnylam Pharmaceuticals Inc. $13,945.00 04/02/2025 Non-covered Recipient Entity
Aqualane Clinical Research
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215511003
Principal investigator 1 Alnylam Pharmaceuticals Inc. $48.00 03/31/2025 Non-covered Recipient Entity
Aqualane Clinical Research
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215511105
Principal investigator 1 Janssen Research & Development, LLC $9,639.00 03/06/2025 Non-covered Recipient Entity
AQUALANE CLINICAL RESEARCH LLC
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175428003
Principal investigator 1 Alnylam Pharmaceuticals Inc. $48.00 02/28/2025 Non-covered Recipient Entity
Aqualane Clinical Research
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215511101
Principal investigator 1 Eli Lilly and Company $112.50 02/25/2025 Non-covered Recipient Entity
COLLIER NEUROLOGIC SPECIALISTS LLC
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 1187876609
Principal investigator 1 Alnylam Pharmaceuticals Inc. $13,945.00 02/21/2025 Non-covered Recipient Entity
Aqualane Clinical Research
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215510942
Principal investigator 1 Alnylam Pharmaceuticals Inc. $14,954.00 02/21/2025 Non-covered Recipient Entity
Aqualane Clinical Research
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215510946
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,261.00 02/21/2025 Non-covered Recipient Entity
Aqualane Clinical Research
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215510950
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,629.73 02/20/2025 Non-covered Recipient Entity
AQUALANE CLINICAL RESEARCH
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184154750
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,036.72 02/20/2025 Non-covered Recipient Entity
AQUALANE CLINICAL RESEARCH
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184154752
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,205.07 02/20/2025 Non-covered Recipient Entity
AQUALANE CLINICAL RESEARCH
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184154754
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,879.61 02/20/2025 Non-covered Recipient Entity
AQUALANE CLINICAL RESEARCH
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184154756
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,959.97 02/20/2025 Non-covered Recipient Entity
AQUALANE CLINICAL RESEARCH
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184154758
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,629.73 02/20/2025 Non-covered Recipient Entity
AQUALANE CLINICAL RESEARCH
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Monotherapy in Patients With Symptomatic Generalized Myasthenia Gravis No dispute reported 06/30/2026 1184154760
Principal investigator 1 Eli Lilly and Company $334,731.00 02/18/2025 Non-covered Recipient Entity
AQUALANE CLINICAL RESEARCH LLC
A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE No dispute reported 06/30/2026 1187873773
Principal investigator 1 Eli Lilly and Company $8,624.00 02/03/2025 Non-covered Recipient Entity
AQUALANE CLINICAL RESEARCH LLC
EVALUATION OF THE LILLY SP-X P-TAU217 ASSAY BY MEASURING CHANGES IN THE INTENDED PATIENT MANAGEMENT BETWEEN PRE-AND POST-P-TAU217 RESULT: A RANDOMIZED CLINICAL UTILITY STUDY No dispute reported 06/30/2026 1187876427
Principal investigator 1 Janssen Research & Development, LLC $17,812.00 02/03/2025 Non-covered Recipient Entity
AQUALANE CLINICAL RESEARCH LLC
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1175427997
Principal investigator 1 Alnylam Pharmaceuticals Inc. $48.00 01/31/2025 Non-covered Recipient Entity
Aqualane Clinical Research
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215511096
Principal investigator 1 Novo Nordisk AS $2,152.80 01/31/2025 Non-covered Recipient Entity
COLLIER NEUROLOGIC SPECIALISTS, LLC
NN6535-4725 No dispute reported 06/30/2026 1213714707
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $372,951.37 01/29/2025 Non-covered Recipient Entity
Aqualane Clinical Research
A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (TargetTau-1) No dispute reported 06/30/2026 1235998967
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $5,174.89 01/27/2025 Non-covered Recipient Entity
Aqualane Clinical Research
A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (TargetTau-1) No dispute reported 06/30/2026 1235998969
Principal investigator 1 Eli Lilly and Company $9,811.59 01/27/2025 Non-covered Recipient Entity
AQUALANE CLINICAL RESEARCH LLC
A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE No dispute reported 06/30/2026 1187880715
Principal investigator 1 Sage Therapeutics, LLC $9,644.43 01/23/2025 Non-covered Recipient Entity
AQUALANE CLINICAL RESEARCH LLC
A Study to Evaluate the Long-term Safety and Tolerability of SAGE-324 in Participants With Essential Tremor No dispute reported 06/30/2026 1206580993
Principal investigator 1 Eli Lilly and Company $27,544.00 01/21/2025 Non-covered Recipient Entity
AQUALANE CLINICAL RESEARCH LLC
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 1187874715
Principal investigator 1 UCB SA $30,932.00 01/07/2025 Non-covered Recipient Entity
AQUALANE CLINICAL RESEARCH LLC
A PATIENT- AND INVESTIGATOR-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF BEPRANEMAB (UCB0107) IN STUDY PARTICIPANTS WITH PRODROMAL TO MILD ALZHEIMERS DISEASE (AD), FOLLOWED BY AN OPEN-LABEL EXTENSION PERIOD No dispute reported 06/30/2026 1246658480